ILMN in one paragraph
ILMN is Illumina's NASDAQ ticker. Roughly $4.4 billion in annual revenue splits across instrument placements (around 20 to 25%), consumable reagents (around 75 to 80%, gross margin materially above the instrument line), and a small services tail. The current re-rating event is the NovaSeq X transition: the new flagship sequencer cuts the cost of a human genome from about $600 to about $200, and the speed at which customers swap NovaSeq 6000 reagents for NovaSeq X reagents (the metric the company calls consumable pull-through) is the swing variable on near-term revenue. At LHFX you trade ILMN as a CFD on MetaTrader 5 with leverage capped at 1:20, raw spreads plus a flat $3 per side commission, and STP/ECN execution. Illumina pays no dividend today; free cash flow is being redeployed into the platform changeover and operating margin recovery after the GRAIL spin-off.
How Illumina actually makes money
Strip the press releases away and Illumina is a chemistry-subscription business wearing a hardware label. The sequencers sit on a benchtop in a lab, get bolted to a service contract, and then consume a steady drip of single-use reagent cartridges every time a tech loads a sample. That repeat consumable spend is where the gross margin sits, not in the machine that ran the first sample. Once a lab has invested staff training and validated pipelines on an Illumina box, switching out to a rival platform means rebuilding the entire workflow, which is why the installed base has historically been so sticky.
The customer mix is broader than most retail investors assume. Academic and government research labs still anchor the base, but clinical diagnostics now drives the growth curve: non-invasive prenatal testing, hereditary cancer panels, minimal residual disease monitoring in oncology, and infectious-disease genomics all run on Illumina chemistry at scale. Pharmaceutical and biotech R&D groups buy throughput for target discovery and biomarker work, and a long tail of direct-to-consumer ancestry and wellness services round out the demand side. Each customer cohort responds to different macro inputs, which is why a single quarterly print can show strong clinical growth alongside a weak biopharma line.
The strategic chapter Illumina just closed is the GRAIL acquisition. GRAIL is a multi-cancer early-detection blood test company that Illumina bought for $7.1 billion in 2021 over the objections of regulators on both sides of the Atlantic. After three years of FTC and European Commission action, the unit was spun out to shareholders in 2024. The spin removed a cash drain and a regulatory overhang in the same motion, and the post-spin story is operating margin recovery rather than diversification.
The metric that matters more than EPS. Consumable pull-through per box is the dollar value of reagents the average installed sequencer pulls each year. NovaSeq 6000 pull-through ran roughly $1.0 to $1.1 million per box at peak. NovaSeq X is targeted at $2 to $3 million per box once fully ramped, but transition-year pull-through can dip well below either number while labs run down old inventory. Every earnings call now leads with this figure.
Where the revenue actually sits
Illumina reports a simple top line, but the buy-side decomposes it into the same five or six lines every quarter. The relative weights below are approximate and shift with the platform cycle; what matters is which lines are growing and which are draining.
| Revenue line | What it captures | Approximate share |
|---|---|---|
| Sequencing consumables | Single-use reagent cartridges, flow cells, and sample-prep kits sold into the installed base of sequencers. Recurring spend, materially higher gross margin than instruments. | ~75 to 80% |
| Sequencing instruments | New NovaSeq X, NextSeq, MiSeq, and NovaSeq 6000 placements. Lumpier, lower gross margin than consumables, but each placement seeds future reagent demand. | ~15 to 18% |
| Service contracts and other | Annual maintenance contracts on the installed base, sequencing-as-a-service revenue, and informatics. Predictable, small in absolute dollars. | ~5 to 8% |
| NovaSeq X mix within instruments | Share of new instrument placements that are the NovaSeq X platform versus the legacy NovaSeq 6000 line. Disclosed each quarter as units shipped and cumulative installed. | Growing, transition variable |
| Clinical share of consumable demand | Portion of consumable revenue tied to clinical labs (prenatal testing, oncology, MRD) rather than research grants. The faster-growing, more recession-resistant slice. | ~45 to 50% |
| Biopharma share of consumable demand | Reagent demand tied to pharma and biotech R&D budgets. Cyclical with biotech sector funding cycles and pharma cost programmes. | ~20 to 25% |
The instrument line gets the headlines, but consumables carry the cash flow and clinical consumables carry the growth. A weak instrument quarter with strong clinical pull-through has historically been bought; a strong instrument quarter with weak pull-through has historically been sold. Read the mix, not the top line.
Earnings cadence and what the buy-side reads first
Illumina reports on a calendar-year schedule, with results landing in early February (Q4 and full year), early May (Q1), early August (Q2), and early November (Q3). Every release drops after the regular cash close, so the first chance to trade the reaction on a CFD product is the next morning's open. The headline EPS number gets the cable-news treatment, but the order in which a buyside analyst reads the release tells you what actually drives the move.
The four lines that get read in the first ninety seconds: NovaSeq X cumulative installed base and units shipped in the quarter, consumable pull-through per box (often stated as a dollar range or year-over-year direction), clinical versus research revenue mix on the consumable line, and forward guidance for next-quarter consumable revenue. EPS and headline revenue come fifth. A beat on EPS that comes with a downward revision to pull-through has produced sharp negative reactions; a miss on EPS combined with stable pull-through and clinical growth has produced strong positive reactions.
Single-session moves on the day after the print have run in the 5 to 12% range during the transition window, with prints around the 2023 NovaSeq X launch producing larger moves on either side. Implied volatility on options into Illumina earnings has stayed elevated since the GRAIL divestiture for the same reason: the pull-through ramp is binary enough on the upside and downside to keep the option market priced for a meaningful gap.
Worked example: sizing for an earnings night
Account size $3,500. ILMN trading at $145. Risk budget for the print: 2% of the account, so $70. You expect an absolute single-session move in the 8 to 12% range and want a sizing that survives the upper bound. At a 12% adverse gap from $145, each share loses $17.40. Dividing $70 by $17.40 gives roughly 4 shares of exposure, or about 0.04 lots on a US single-stock CFD. Margin requirement at 1:20 is around $29, well under the cap. Round-trip commission on 4 shares is trivial against the loss budget. The discipline is to size to the gap you actually expect, not to the leverage the platform will let you take.
What moves ILMN day to day
Outside earnings windows, ILMN reacts to a tight cluster of inputs. These seven explain the bulk of the daily and quarterly variance, and the buy-side watches each one on a different cadence.
Consumable pull-through per NovaSeq X box
The dollar value of reagents the average installed sequencer pulls each year. Disclosed every quarter, sometimes as an explicit range and sometimes through qualitative commentary on the call. Pull-through running below plan compresses the multi-year revenue model; pull-through running ahead re-rates the stock immediately.
NovaSeq X cumulative installations
Total units placed and quarterly net adds tell you how fast the new platform is replacing the old. Slow installs mean slow consumable ramp; accelerated installs pull future revenue forward. Management calls out specific install counts on the call rather than leaving them in the appendix.
Clinical sequencing volume growth
Reproductive health screening, oncology panels, and minimal residual disease testing carry higher growth rates than research volume and are less exposed to academic grant cycles. Quarterly clinical-mix disclosure feeds the underlying growth multiple on the stock.
Competitive disclosures
Element Biosciences, Ultima Genomics, MGI, and Pacific Biosciences on the long-read side have all launched platforms with aggressive pricing. Any quarterly evidence of customer defection, sample-prep contract loss, or pricing concession around a major lab tender feeds straight into the share price.
Operating margin recovery trajectory
After heavy losses through the GRAIL ownership era, post-spin management has committed to a multi-year operating margin recovery programme. Quarter-on-quarter progression on operating margin, headcount, and capex efficiency is reviewed at the same intensity as the revenue lines.
Biopharma R&D budgets
Pharma and biotech R&D departments are a meaningful portion of consumable demand. Sector funding downturns and pharma cost programmes flow through to instrument and reagent demand on a one- to two-quarter lag. Biotech sentiment headlines often move ILMN sympathetically.
Medical and genomics conference cadence
AGBT in February, ASCO in early June, and ASHG in October are the three windows where Illumina typically times product announcements, partnership reveals, or new application launches. Sessions before and during these conferences can produce news-driven moves outside the earnings calendar.
When ILMN trades
ILMN is listed on the NASDAQ Global Select Market and trades on the standard US cash-equity schedule. The single most important point: ILMN as an LHFX CFD trades only during the regular cash session, so the after-hours window where every earnings print actually lands is unavailable to you as a CFD trader. The move gets priced in by the time the regular bell rings the next morning.
Pre-market (cash equity)
4:00 AM to 9:30 AM ET. Thin liquidity, wide spreads. Where overnight headlines on competing sequencer announcements, FDA test approvals, or European medical conference output get an initial print. Not available as an LHFX CFD.
Regular session
9:30 AM to 4:00 PM ET, Monday to Friday. The full liquidity window. Typical daily range on ILMN runs 2.0 to 3.0% in normal weeks, expanding to 8 to 15% on earnings-reaction days and 4 to 7% on major conference disclosures or competitor product launches.
After-hours (cash equity)
4:00 PM to 8:00 PM ET. Where every quarterly print lands. The initial 30-minute reaction tells you whether pull-through, install count, or guidance is being received well or badly. Spreads are wide and the move is choppy. Not available as an LHFX CFD.
ILMN CFD hours at LHFX
Regular NASDAQ session only: 14:30 to 21:00 UTC (13:30 to 20:00 UTC during US daylight time), Monday to Friday, excluding US market holidays. Any earnings or conference move that happens outside this window gets compressed into the next morning's opening print, so positions held into the close carry the full overnight gap.
Holding an ILMN CFD across an earnings night, an ASCO data drop, or a competitor launch headline means you take the full gap on the next open with no chance to manage the trade in between. The CFD reopens at whatever the after-hours tape printed. Size the position against the gap, not against the margin allowance.
ILMN CFD vs direct share ownership vs genomics ETF
You can take a directional view on Illumina three obvious ways: a CFD on ILMN at LHFX, the underlying common share through a cash-equity broker, or a thematic ETF that holds Illumina alongside its sequencing and diagnostics peers. They share a price feed and differ on almost everything else.
| Product | Ownership | Dividends | Leverage | Cost structure |
|---|---|---|---|---|
| ILMN CFD | Contract only, no underlying share | None on ILMN today, since Illumina pays no dividend | Up to 1:20 | Raw spread plus $3 per side commission plus overnight swap |
| Direct ILMN share | Registered holder, voting rights, paper or DTC custody | None paid by Illumina at present | Reg T margin only, typically 2:1 if approved | Broker commission plus bid-ask, no swap |
| Genomics ETF | ETF share, indirect holding | Pass-through of any distributions from holdings | Reg T only, or a leveraged ETF wrapper | Bid-ask plus annual management fee typically 0.45 to 0.75% |
Use the CFD when you want short-dated directional exposure with leverage, intraday entries and exits, and symmetrical short access without locating borrow. Use direct shares for multi-year ownership and any future dividend reinstatement. Use a genomics ETF when you want sector exposure without the single-platform transition risk that ILMN carries on its own. None of the three is universally better; they solve different jobs.
Trading ILMN at LHFX
LHFX offers ILMN as a CFD on MetaTrader 5 with STP/ECN execution and no dealing desk. The full specification, including current contract size and any active swap rate, is visible inside MT5 under Market Watch, Symbols, ILMN. Settlement is in USD regardless of your account base currency, so a non-USD account converts realised P&L on close.
Up to 1:20 on ILMN, the cap that applies to US single-stock CFDs. The combination of the platform transition and earnings reaction profile means a fully sized position at the cap is exposed to a single-event wipe of the deposited margin. Most experienced traders run effective leverage between 1:3 and 1:6 on ILMN.
$3 per side, $6 round-trip, applied per standard lot. Charged as a flat fee on top of a raw spread rather than embedded inside a marked-up spread, so the total cost stays visible on every fill.
MetaTrader 5 across Windows, Mac, web, iOS, and Android. LHFX is a direct MetaQuotes licensee, so ILMN sits in the same Market Watch as forex pairs, indices, commodities, and crypto on a single account.
STP/ECN. Orders pass straight through to aggregated equity liquidity. There is no in-house position taken against your fill and no dealing-desk requote layer between the click and the market.
Regular NASDAQ session only, Monday to Friday. Pre-market and after-hours moves get compressed into the opening print the following session.
Variable, tightest in the middle of the cash session. Spreads widen at the open, at the close, around earnings, and during medical-conference data drops. Always check the live spread inside MT5 before placing a sized order around a known event.
A different sizing example
Account $3,500. ILMN at $145. You want a swing-trade long with room for an ordinary 3% daily wobble before getting stopped. A 0.05 lot CFD position controls 5 shares, notional $725. Margin at 1:20 works out to roughly $36, about 1% of the account. A 3% adverse move from $145 to $140.65 costs $21.75. A 10% earnings gap, which is plausible on this name, costs $72.50, just over 2% of the account. Round-trip commission on 5 shares is small relative to the loss budget. The takeaway: sizing to the gap you can actually be wrong against, rather than to the leverage cap, is what keeps an ILMN swing trade survivable across a print.
For current spread snapshots, contract size, and the live swap rate, see the ILMN instrument page. For the full commission schedule across all CFDs, see spreads and fees, and for the leverage policy by instrument see leverage.
Risks specific to trading ILMN
Two stock-level risks stack on top of the standard equity-CFD profile, and both can produce single-session moves large enough to invalidate any sensible stop placement. Treat earnings windows and any pre-announced conference data drop as separate risk regimes.
Pull-through ramp shortfall
If consumable revenue per NovaSeq X box ramps below plan, the entire recovery model rerates lower. Customers running down old NovaSeq 6000 reagent stockpiles before switching to new chemistry can produce a quarter or two of soft pull-through that looks structural. Sustained shortfall produces multiple compression on top of the revenue miss.
Competitive share loss in the transition window
Element Biosciences, Ultima Genomics, MGI, and Pacific Biosciences have launched sequencers at lower price points than NovaSeq X. The transition window is the moment a lab can rebuild its workflow around a cheaper platform without already-sunk Illumina training getting in the way. Any quarter showing material defection at a flagship clinical or research customer historically produces an outsized down move.
Leverage compounds in both directions
At 1:20, a 5% adverse move on a fully sized ILMN position consumes the deposited margin on that trade entirely. With single-day moves of 10 to 15% routine around earnings and conferences, the margin cap is not the right anchor for sizing. Effective leverage of 1:3 to 1:6 is the working norm for cash equity CFDs on a name with this volatility profile.
Earnings and after-hours gap risk
Every quarterly print and most major conference announcements land outside the regular session, which is the window LHFX trades ILMN. A stop loss cannot fill across a closed market. Positions held into the close are exposed to the full overnight reaction, and the CFD reopens at whatever the after-hours market settled on.
Risk disclosure: CFDs are complex instruments that carry a high risk of losing money rapidly because of leverage. The majority of retail trading accounts lose money on CFDs. You should consider whether you understand how CFDs work and whether you can afford the risk of losing the funds you commit. Trade only with money you can afford to lose entirely.